Cancer Institute– A national cancer institute
designated cancer center

Sunil Reddy

Back to Profile

Publication Details

  • A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders.

    Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL, Kim YH. Clin Cancer Res. 2009; 15 (19): 6217-24

    An open-label, multicenter, phase II study was conducted to define the safety and antitumor activity of the monoclonal antibody SGN-30 in patients with CD30(+) primary cutaneous anaplastic large cell lymphoma (pc-ALCL), lymphomatoid papulosis (LyP), or transformed mycosis fungoides (T-MF).

    PubMedID: 19789316

Stanford Medicine Resources:

Footer Links: